Fortis cancels plan to merge SRL, Fortis Malar
Fortis Healthcare has withdrawn the scheme of arrangement and amalgamation between its subsidiary Fortis Malar Hospitals and its diagnostics arm SRL Ltd, citing delay in completion of the process and strong headwinds in the sector. Sources said the plan was called off due to technical reasons.
Fortis Healthcare Ltd (FHL) withdrew the scheme of arrangement and amalgamation between its step-down subsidiary Fortis Malar Hospitals, a listed entity and its diagnostics arm SRL Ltd, citing delay in completion of the process and strong headwinds in the sector.
Sources close to the development said the plan was called off primarily for technical reasons (delay in completion) and since FHL is on the block, the management felt that it would be best for the new buyer to take a call on the structure of the businesses. The Fortis Malar stock reacted positively to the decision and the scrip closed at ~51.85 a share, up 0.68 per cent.
The plan was proposed in August 2016 and ideally should have taken six to eight months to complete. In a late night filing to the exchanges on Wednesday, FHL said, "The entire process was expected to take six to eight months, however, due to reasons beyond the company's control, the process took over 19 months and is still not complete." The scheme is currently pending for approval with the National Company Law Tribunal (NCLT), Chandigarh bench, it said.
According to the original plan, FHL was to hive off its diagnostic arm SRL to Fortis Malar Hospitals. SRL and Fortis Malar were to become one entity and be called SRL. In turn, Fortis Malar was to sell its Chennai facility to FHL by way of a slump sale for ~430 million.
Fortis said during the past 19 months, the health care sector has witnessed strong headwinds and performance of the diagnostics business has not been ‘optimum’. “Given the challenges/headwinds in the sector and less than optimum performance of the diagnostics business during the period of delay, the demerger and a subsequent listing may result in value unlocking that may not be optimum for Fortis shareholders at this point of time,” it added.
Promoter and promoter group hold 62.9 per cent in Fortis Malar.
Malvinder Singh and entities related to him including Fortis Healthcare Holding, Fortis Hospitals Ltd, Malav Holdings, RHC Holdings are among the promoter
group entities.
According to market sources, one of the rationales behind the decision to scrap the amalgamation might have been to keep the Singh brothers away from SRL. Fortis Malar has a market capitalisation of ~968 million as on June 14, 2018. SRL, a subsidiary of FHL, is valued at ~50 billion.
“The valuation of Fortis Malar is quite low. Given the high valuation of SRL, the promoters of Fortis Malar would have not got more than 2 or 3 per cent stake in SRL,” said someone who is in race to buy Fortis Healthcare.